Home » Healthcare » Pharmaceuticals » China Diabetes Drugs Market

China Diabetes Drugs Market

China Diabetes Drugs Market By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Others); By Diabetes Types (Type 1, Type 2, Diabetes Type 3, Diabetes Type 4, Diabetes Type 5); By Route of Administration (Oral, Subcutaneous, Intravenous, Route of Administration 4, Route of Administration 5); By Technology (Technology 1, Technology 2, Technology 3); By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, Distribution Channel 4, Distribution Channel 5) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
China Diabetes Drugs Market Size 2024	USD 9,595.27 million
China Diabetes Drugs Market, CAGR	5.11%
China Diabetes Drugs Market Size 2032	USD 15,556.98 million

Market Overview

China Diabetes Drugs market size was valued at USD 9,595.27 million in 2023 and is anticipated to reach USD 15,556.98 million by 2032, at a CAGR of 5.11% during the forecast period (2023-2032).

The China diabetes drugs market is driven by a rising prevalence of diabetes, fueled by an aging population, urbanization, and changing lifestyles. Government initiatives to improve diabetes management, increasing healthcare expenditure, and advancements in drug development, including GLP-1 receptor agonists and SGLT-2 inhibitors, further support market growth. The expansion of digital healthcare and telemedicine enhances patient access to treatment and monitoring. Additionally, growing collaborations between domestic and global pharmaceutical companies foster innovation and market penetration. The shift towards personalized medicine and biosimilars is also gaining traction, offering cost-effective treatment alternatives. Favorable regulatory reforms, such as expedited drug approvals and reimbursement policies, are accelerating the availability of new therapies. Moreover, increased awareness and screening programs contribute to early diagnosis and treatment adherence.

China’s diabetes drugs market is expanding rapidly, with key geographical regions such as Beijing, Shanghai, Guangzhou, and Shenzhen leading in demand due to their advanced healthcare infrastructure and high diabetes prevalence. Urban centers benefit from better access to innovative treatments, while rural areas still face challenges in affordability and availability of advanced therapies. The market is highly competitive, with global pharmaceutical giants such as Novo Nordisk, Sanofi, Merck & Co., Eli Lilly, and AstraZeneca dominating insulin and oral antidiabetic drug segments. Domestic players like Chongqing Fujin Biology Medical Company and Hisun Pharma are also gaining traction by offering cost-effective alternatives. The increasing adoption of digital health technologies and biosimilars is reshaping market dynamics, while government policies promoting diabetes management further drive growth. As pharmaceutical companies continue investing in research and development, China remains a crucial market for diabetes drug innovation and expansion.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The China diabetes drugs market was valued at USD 9,595.27 million in 2023 and is expected to reach USD 15,556.98 million by 2032, growing at a CAGR of 5.11% from 2023 to 2032.
Rising diabetes prevalence due to lifestyle changes, aging population, and urbanization is driving market growth.
Increasing adoption of innovative therapies like GLP-1 receptor agonists and SGLT2 inhibitors is transforming diabetes treatment.
Leading pharmaceutical companies such as Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca dominate the market, while domestic players are expanding with cost-effective alternatives.
High treatment costs, limited access in rural areas, and complex regulatory approvals act as major market restraints.
Beijing, Shanghai, Guangzhou, and Shenzhen are key regions driving demand due to advanced healthcare infrastructure and high patient populations.
Government initiatives, digital health integration, and biosimilar adoption are reshaping the market landscape for long-term growth.

Report scope

This reports segments are China Diabetes Drugs Market as Follows;

Market Drivers

Rising Prevalence of Diabetes and Aging Population

The increasing prevalence of diabetes in China is a primary driver of the diabetes drugs market. A sedentary lifestyle, unhealthy dietary habits, and rising obesity rates contribute significantly to the growing number of diabetic patients. For instance, the International Diabetes Federation reported that China has the largest diabetic population globally, with over 140 million adults living with diabetes. Additionally, the country’s aging population plays a critical role in the surge of diabetes cases, as older individuals are at higher risk of developing type 2 diabetes. This demographic shift is expected to drive the demand for effective diabetes treatments and innovative drug formulations, supporting steady market growth.

Government Initiatives and Healthcare Reforms

The Chinese government has been actively implementing policies to improve diabetes management and enhance access to treatment. For instance, the inclusion of diabetes drugs in the National Reimbursement Drug List (NRDL) has reduced out-of-pocket expenses for patients, making advanced therapies more accessible. Additionally, government-led initiatives such as the “Healthy China 2030” plan aim to enhance diabetes awareness, early diagnosis, and disease prevention strategies. Regulatory agencies have also streamlined the approval process for innovative diabetes drugs, encouraging pharmaceutical companies to introduce novel treatments in the Chinese market. These supportive measures are expected to drive the expansion of the diabetes drugs industry over the forecast period.

Advancements in Drug Development and Innovation

Pharmaceutical companies in China are increasingly investing in research and development to introduce next-generation diabetes drugs. The adoption of GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors has significantly improved diabetes treatment outcomes, offering patients more effective and convenient therapeutic options. The rise of biosimilars and personalized medicine is also transforming the market, providing cost-effective alternatives to traditional diabetes treatments. Additionally, the integration of artificial intelligence and big data in drug discovery is accelerating the development of innovative therapies, improving disease management, and enhancing patient adherence. These advancements are expected to fuel market growth and position China as a key player in the global diabetes drug industry.

Expanding Digital Healthcare and Telemedicine

The rapid expansion of digital healthcare solutions and telemedicine is reshaping diabetes management in China. The widespread adoption of mobile health applications, wearable devices, and remote monitoring technologies enables patients to track their blood glucose levels in real time and receive timely medical interventions. The integration of digital platforms with diabetes treatment has improved patient engagement, medication adherence, and overall disease outcomes. Furthermore, the collaboration between pharmaceutical companies and technology firms has led to the development of AI-powered healthcare solutions, offering personalized treatment plans based on patient data. This digital transformation is expected to drive the demand for innovative diabetes drugs and enhance accessibility to effective treatments, contributing to market growth.

Market Trends

Growing Adoption of Innovative Drug Therapies

The China diabetes drugs market is witnessing a shift toward innovative therapies, driven by advancements in drug development and increasing demand for effective treatment options. GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors are gaining traction due to their superior efficacy and lower risk of adverse effects compared to traditional diabetes treatments. For instance, a report by the Chinese Diabetes Society highlights that GLP-1 receptor agonists have demonstrated significant cardiovascular benefits in clinical trials, leading to their widespread adoption among healthcare professionals. Additionally, pharmaceutical companies such as Innogen Pharma have introduced next-generation diabetes drugs, including efsubaglutide alfa, which offers improved glycemic control and reduced dosing frequency.

Expansion of Biosimilars and Cost-Effective Treatments

With rising healthcare costs, the demand for biosimilar insulin and generic diabetes drugs is increasing in China. Biosimilars provide affordable alternatives to branded biologics while maintaining similar efficacy and safety profiles. For instance, Hangzhou Jiuyuan Gene Engineering has developed Jiyoutai, a biosimilar version of Novo Nordisk’s Ozempic, which has completed late-stage clinical trials and is awaiting regulatory approval. The Chinese government’s support for domestic pharmaceutical manufacturing and favorable regulatory policies are driving the growth of biosimilars in the diabetes drugs market. Additionally, local pharmaceutical companies are focusing on producing high-quality, cost-effective diabetes medications to compete with international brands. As more biosimilars receive regulatory approval and enter the market, affordability and accessibility of diabetes treatment are expected to improve, benefiting a larger patient population.

Integration of Digital Health and AI in Diabetes Management

The integration of digital health solutions and artificial intelligence (AI) is transforming diabetes management in China. Mobile health applications, AI-powered diagnostic tools, and smart insulin delivery systems are enhancing patient adherence and treatment outcomes. Telemedicine platforms are expanding access to diabetes care, particularly in rural areas where specialized healthcare services are limited. Pharmaceutical companies are also collaborating with technology firms to develop AI-driven solutions that provide personalized treatment recommendations based on real-time patient data. These advancements are not only improving disease monitoring but also optimizing drug efficacy, leading to better diabetes management and higher demand for innovative medications.

Increased Focus on Preventive Healthcare and Early Diagnosis

The rising awareness of diabetes prevention and early diagnosis is shaping market trends in China. Government-led health initiatives and public awareness campaigns emphasize lifestyle modifications, regular screening, and early intervention to reduce diabetes-related complications. The growing adoption of continuous glucose monitoring (CGM) devices and point-of-care testing is enabling earlier detection and better disease control. As a result, the demand for preventive treatments, including oral antidiabetic drugs and lifestyle-focused therapeutics, is increasing. Pharmaceutical companies are responding by developing drugs that not only manage blood sugar levels but also address metabolic risk factors associated with diabetes. This trend is expected to drive long-term market growth and improve patient outcomes.

Market Challenges Analysis

High Treatment Costs and Limited Accessibility

Despite advancements in diabetes drug development, high treatment costs remain a significant challenge in China. Many innovative diabetes medications, including GLP-1 receptor agonists and SGLT-2 inhibitors, are expensive, limiting their accessibility for a large segment of the population, particularly in rural and underdeveloped regions. While the government has taken steps to include some diabetes drugs in the National Reimbursement Drug List (NRDL), affordability remains a concern, especially for long-term treatments. Additionally, disparities in healthcare infrastructure contribute to uneven access to advanced diabetes therapies, with urban areas benefiting from better medical facilities and treatment options compared to rural regions. The challenge of ensuring widespread and affordable access to effective diabetes medications continues to be a barrier to market expansion.

Regulatory Hurdles and Market Competition

The complex regulatory landscape in China poses another challenge for the diabetes drugs market. While regulatory reforms have streamlined drug approval processes, stringent requirements for clinical trials and market entry create barriers for new drug development. For instance, data from the National Medical Products Administration (NMPA) indicates that over 1,200 diabetes drug trials were registered between 2013 and 2023, with many facing delays due to rigorous safety and efficacy evaluations. Pharmaceutical companies must navigate an evolving regulatory environment, which can lead to delays in product approvals and commercialization. Additionally, the market is becoming increasingly competitive, with both domestic and international pharmaceutical companies vying for market share. The growing presence of biosimilars and generic alternatives further intensifies competition, putting pressure on pricing and profitability for branded drug manufacturers. As companies strive to balance innovation with cost-effectiveness, overcoming regulatory and competitive challenges will be crucial for sustained market growth.

Market Opportunities

China’s diabetes drugs market presents significant growth opportunities driven by increasing healthcare investments and a rising focus on chronic disease management. The government’s commitment to improving diabetes care through policies such as the National Reimbursement Drug List (NRDL) expansion and public health initiatives enhances access to advanced therapies. With the growing prevalence of diabetes, pharmaceutical companies have opportunities to develop and introduce innovative treatments, including next-generation oral antidiabetic drugs, biosimilars, and combination therapies. The increasing adoption of precision medicine and personalized treatment approaches further supports market expansion, as tailored therapies improve patient outcomes and adherence. Additionally, multinational pharmaceutical firms continue to strengthen their presence through strategic partnerships and local manufacturing, fostering a competitive yet dynamic market landscape.

The integration of digital health technologies and artificial intelligence (AI) in diabetes management presents another major opportunity. The widespread use of mobile health applications, telemedicine, and continuous glucose monitoring (CGM) devices is transforming disease monitoring and patient engagement. As China’s digital healthcare ecosystem grows, pharmaceutical companies can leverage AI-driven analytics to optimize treatment plans and improve drug efficacy. Furthermore, the shift toward preventive healthcare and early intervention opens new avenues for developing lifestyle-based therapeutics and health management programs. With continued regulatory support, innovation in diabetes drug development, and advancements in healthcare infrastructure, China’s diabetes drugs market is poised for sustained growth and enhanced patient care in the coming years.

Market Segmentation Analysis:

By Drug Class:

The China diabetes drugs market is segmented by drug class, including insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and other medications. Insulin remains a dominant segment due to its essential role in managing type 1 and advanced type 2 diabetes. The increasing adoption of biosimilar insulin is further expanding this segment, making treatment more accessible and cost-effective. DPP-4 inhibitors continue to gain traction as they offer effective glycemic control with minimal side effects, making them a preferred choice for early-stage type 2 diabetes management. Meanwhile, GLP-1 receptor agonists are growing rapidly due to their dual benefits of blood sugar control and weight loss, making them increasingly popular among obese diabetic patients. SGLT2 inhibitors are emerging as a transformative drug class, providing not only glycemic control but also cardiovascular and renal benefits. The “Others” category includes traditional oral antidiabetic drugs and emerging therapies, reflecting ongoing innovations in diabetes treatment. As research advances, the market is expected to witness further diversification in drug offerings.

By Diabetes Types:

Diabetes drugs in China are categorized based on diabetes types, including type 1, type 2, and rarer forms such as type 3, type 4, and type 5 diabetes. Type 2 diabetes dominates the market, driven by its high prevalence due to lifestyle factors such as poor diet, obesity, and sedentary habits. With an aging population and rising obesity rates, the demand for type 2 diabetes drugs, particularly oral antidiabetics and combination therapies, is expected to surge. Type 1 diabetes, though less common, remains a significant segment requiring lifelong insulin therapy. The demand for advanced insulin formulations and automated insulin delivery systems is increasing to improve patient convenience and glycemic control. Type 3, type 4, and type 5 diabetes, though less understood, are gaining attention in medical research, leading to the development of specialized treatment approaches. As diagnostic capabilities improve, pharmaceutical companies have opportunities to expand their product portfolios and address the needs of these niche patient populations.

Segments:

Based on Drug Class:

Insulin
DPP-4 Inhibitors
GLP-1 Receptor Agonists
SGLT2 Inhibitors
Others

Based on Diabetes Types:

Type 1
Type 2
Diabetes Type 3
Diabetes Type 4
Diabetes Type 5

Based on Route of Administration:

Oral
Subcutaneous
Intravenous
Route of Administration 4
Route of Administration 5

Based on Technology:

Technology 1
Technology 2
Technology 3

Based on Distribution Channel:

Online Pharmacies
Hospital Pharmacies
Retail Pharmacies
Distribution Channel 4
Distribution Channel 5

Based on the Geography:

Beijing
Shanghai
Guangzhou
Shenzhen

Regional Analysis

Beijing

Beijing holds the largest share of China’s diabetes drugs market, accounting for approximately 28% of the total market. As the political and medical hub of China, Beijing benefits from well-established healthcare infrastructure, leading research institutions, and access to advanced diabetes treatments. The presence of top-tier hospitals and research centers facilitates early adoption of innovative therapies, including GLP-1 receptor agonists and SGLT2 inhibitors. Government-backed healthcare programs and strong reimbursement policies further enhance patient access to diabetes medications. Additionally, Beijing’s aging population and high urbanization rates contribute to the increasing demand for diabetes treatments. With continuous investment in medical research and digital health solutions, the region is expected to maintain its leadership in diabetes drug consumption and innovation.

Shanghai

Shanghai follows closely with a 25% share of the diabetes drugs market, driven by its advanced healthcare system and strong pharmaceutical industry presence. As a leading economic hub, Shanghai attracts multinational pharmaceutical companies, fostering the development and commercialization of next-generation diabetes therapies. The city has a high prevalence of diabetes due to its aging demographic and sedentary lifestyle patterns. In response, Shanghai has implemented comprehensive diabetes management programs, integrating telemedicine and artificial intelligence into treatment strategies. The growing adoption of digital health technologies, such as continuous glucose monitoring (CGM) devices and AI-powered diabetes management platforms, further strengthens the region’s market position. With ongoing investments in biotechnology and healthcare innovation, Shanghai is set to experience continued growth in the diabetes drugs sector.

Guangzhou

Guangzhou holds a 22% share of China’s diabetes drugs market, supported by its expanding healthcare infrastructure and increasing diabetes prevalence. The city serves as a key gateway for international pharmaceutical trade, enabling faster access to innovative diabetes treatments. Guangzhou’s rising middle-class population and improving healthcare accessibility contribute to the demand for advanced diabetes medications, including biosimilar insulin and combination therapies. Additionally, government initiatives promoting diabetes awareness and early screening programs have significantly improved disease detection and management. The region is also investing in research collaborations with international pharmaceutical firms, accelerating the introduction of cost-effective and efficient diabetes drugs. As Guangzhou continues to modernize its healthcare sector, its market share is expected to grow steadily.

Shenzhen

Shenzhen accounts for 20% of China’s diabetes drugs market, driven by rapid technological advancements and a strong focus on digital healthcare. As China’s innovation hub, Shenzhen is at the forefront of integrating artificial intelligence and smart medical devices into diabetes care. The city’s pharmaceutical sector is expanding rapidly, with numerous biotech startups and established firms developing novel diabetes treatments. Shenzhen’s highly urbanized and fast-paced lifestyle has contributed to a rising diabetes burden, increasing the demand for effective and convenient treatment options. The adoption of mobile health applications, smart insulin delivery systems, and remote monitoring solutions is transforming diabetes management in the region. With continued investments in digital health and biopharmaceutical research, Shenzhen is poised to become a key player in the evolution of China’s diabetes drug market.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Novo Nordisk A/S
Sanofi
Merck & Co., Inc.
Eli Lilly and Company
AstraZeneca
Takeda Pharmaceutical Company Limited
Boehringer Ingelheim International GmbH
Novartis AG
Johnson & Johnson Services, Inc.
Bayer AG
Chongqing Fujin Biology Medical Company
Hisun Pharma

Competitive Analysis

The China diabetes drugs market is highly competitive, with both global pharmaceutical giants and domestic players striving for market dominance. Leading multinational companies, including Novo Nordisk, Sanofi, Merck & Co., Eli Lilly, AstraZeneca, Takeda Pharmaceutical, Boehringer Ingelheim, Novartis, Johnson & Johnson, and Bayer, hold a significant share due to their strong product portfolios, innovative drug pipelines, and established market presence. These companies continuously invest in R&D, strategic collaborations, and digital healthcare solutions to strengthen their market presence. Meanwhile, domestic pharmaceutical companies are expanding their footprint by offering cost-effective biosimilars and generic alternatives, making diabetes treatment more accessible. Competitive pricing strategies and government support for local drug manufacturers are driving their market penetration. The increasing adoption of biosimilars, personalized medicine, and AI-driven diabetes management is intensifying competition. Companies are focusing on expanding their product portfolios, optimizing distribution networks, and leveraging technological advancements to enhance patient outcomes and maintain a strong market position in this rapidly evolving landscape.

Recent Developments

In March 2025, Novo Nordisk signed a deal worth up to $2 billion for the rights to UBT251, a new obesity and diabetes drug developed by United BioTechnology. The drug combines GLP-1, GIP, and glucagon to manage blood sugar and reduce hunger.
In February 2025, Sanofi received FDA approval for MERILOG, the first rapid-acting insulin aspart biosimilar, to improve glycemic control in adults and pediatric patients with diabetes.
In December 2024, JD Health began offering Merck’s GLUCOPHAGE XR (Reduce Mass) online in China, enhancing access to metformin hydrochloride extended-release tablets for type 2 diabetes patients.
In December 2024, Torrent Pharma acquired three diabetes brands from Boehringer Ingelheim, including those with Empagliflozin, to strengthen its anti-diabetes portfolio
In November 2024, AstraZeneca presented promising early data for its obesity pipeline, including AZD5004, an oral GLP-1 receptor blocker, at ObesityWeek 2024.

Market Concentration & Characteristics

The China diabetes drugs market is moderately concentrated, with a mix of global pharmaceutical giants and emerging domestic players shaping the competitive landscape. Leading multinational companies dominate the market with patented insulin therapies, advanced oral antidiabetics, and novel drug formulations, leveraging their strong research and development capabilities. Meanwhile, domestic manufacturers are expanding their presence by introducing cost-effective biosimilars and generic alternatives, intensifying competition. The market is characterized by high demand for innovative treatments, increasing adoption of biosimilars, and a shift toward personalized medicine. Government policies, including price regulations and reimbursement programs, influence market dynamics by promoting affordability and accessibility. Additionally, the integration of digital health technologies, AI-driven diabetes management, and telemedicine solutions is transforming treatment approaches. As companies continue to invest in product innovation and strategic partnerships, the market is expected to witness steady growth while evolving to meet the rising healthcare needs of China’s diabetic population.

Report Coverage

The research report offers an in-depth analysis based on Drug Class, Diabetes Types, Route of Administration, Technology, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The China diabetes drugs market will continue to grow steadily, driven by increasing diabetes prevalence and aging demographics.
Innovation in drug development, including next-generation insulin and oral antidiabetics, will enhance treatment options.
Biosimilars and generic alternatives will gain market traction, improving affordability and accessibility.
Government policies and reimbursement programs will support wider adoption of advanced diabetes therapies.
Digital health solutions, AI-driven analytics, and telemedicine will play a crucial role in diabetes management.
Pharmaceutical companies will invest heavily in R&D to develop personalized and precision-based treatments.
Market competition will intensify as domestic players expand their presence with cost-effective alternatives.
The demand for combination therapies and novel drug delivery systems will continue to rise.
Urban centers will drive innovation and early adoption of advanced treatments, while rural areas will see gradual improvements in access.
Strategic partnerships and global collaborations will shape the future of China’s diabetes drugs market.

CHAPTER NO. 1 : INTRODUCTION 19

1.1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.1.2. Key Benefits for Stakeholders 19

1.1.3. Target Audience 20

1.1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. DIABETES DRUGS Market Snapshot 21

2.1.1. China DIABETES DRUGS Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23

3.1. Russia-Ukraine and Israel-Palestine War Impacts 23

CHAPTER NO. 4 : DIABETES DRUGS MARKET – INDUSTRY ANALYSIS 24

4.1. Introduction 24

4.2. Market Drivers 25

4.2.1. Driving Factor 1 Analysis 25

4.2.2. Driving Factor 2 Analysis 26

4.3. Market Restraints 27

4.3.1. Restraining Factor Analysis 27

4.4. Market Opportunities 28

4.4.1. Market Opportunity Analysis 28

4.5. Porter’s Five Forces Analysis 29

4.6. Value Chain Analysis 30

4.7. Buying Criteria 31

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32

5.1. Import Analysis by China 32

5.1.1. China DIABETES DRUGS Market Import Volume/Revenue, By China, 2018 – 2023 32

5.2. Export Analysis by China 33

5.2.1. China DIABETES DRUGS Market Export Volume/Revenue, By China, 2018 – 2023 33

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34

6.1. Demand Analysis by China 34

6.1.1. China DIABETES DRUGS Market Demand Volume/Revenue, By China, 2018 – 2023 34

6.2. Supply Analysis by China 35

6.2.1. China DIABETES DRUGS Market Supply Volume/Revenue, By China, 2018 – 2023 35

CHAPTER NO. 7 : PRODUCTION ANALYSIS 36

7.1. Production Analysis by China 36

7.1.1. China DIABETES DRUGS Market Production Volume/Revenue, By China, 2018 – 2023 36

CHAPTER NO. 8 : PRICE ANALYSIS 37

8.1. Price Analysis by Drug Class 37

8.1.1. China DIABETES DRUGS Market Price, By Drug Class, 2018 – 2023 37

8.1.2. China Drug Class Market Price, By Drug Class, 2018 – 2023 37

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38

9.1. Key Raw Materials and Suppliers 38

9.2. Key Raw Materials Price Trend 38

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39

10.1. Manufacturing Cost Analysis 39

10.2. Manufacturing Process 39

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40

11.1. Company Market Share Analysis – 2023 40

11.1.1. China DIABETES DRUGS Market: Company Market Share, by Volume, 2023 40

11.1.2. China DIABETES DRUGS Market: Company Market Share, by Revenue, 2023 41

11.1.3. China DIABETES DRUGS Market: Top 6 Company Market Share, by Revenue, 2023 41

11.1.4. China DIABETES DRUGS Market: Top 3 Company Market Share, by Revenue, 2023 42

11.2. China DIABETES DRUGS Market Company Volume Market Share, 2023 43

11.3. China DIABETES DRUGS Market Company Revenue Market Share, 2023 44

11.4. Company Assessment Metrics, 2023 45

11.4.1. Stars 45

11.4.2. Emerging Leaders 45

11.4.3. Pervasive Players 45

11.4.4. Participants 45

11.5. Start-ups /SMEs Assessment Metrics, 2023 45

11.5.1. Progressive Companies 45

11.5.2. Responsive Companies 45

11.5.3. Dynamic Companies 45

11.5.4. Starting Blocks 45

11.6. Strategic Developments 46

11.6.1. Acquisitions & Mergers 46

New Product Launch 46

China Expansion 46

11.7. Key Players Product Matrix 47

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48

12.1. PESTEL 48

12.1.1. Political Factors 48

12.1.2. Economic Factors 48

12.1.3. Social Factors 48

12.1.4. Technological Factors 48

12.1.5. Environmental Factors 48

12.1.6. Legal Factors 48

12.2. Adjacent Market Analysis 48

CHAPTER NO. 13 : DIABETES DRUGS MARKET – BY DRUG CLASS SEGMENT ANALYSIS 49

13.1. DIABETES DRUGS Market Overview, by Drug Class Segment 49

13.1.1. DIABETES DRUGS Market Revenue Share, By Drug Class, 2023 & 2032 50

13.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Drug Class 51

13.1.3. Incremental Revenue Growth Opportunity, by Drug Class, 2024 – 2032 51

13.1.4. DIABETES DRUGS Market Revenue, By Drug Class, 2018, 2023, 2027 & 2032 52

13.2. Insulin 53

13.3. Dpp-4 Inhibitors 54

13.4. GLP-1 Receptor Agonists 55

13.5. SGLT2 Inhibitors 56

13.6. Others 57

CHAPTER NO. 14 : DIABETES DRUGS MARKET – BY DIABETES TYPES SEGMENT ANALYSIS 58

14.1. DIABETES DRUGS Market Overview, by Diabetes Types Segment 58

14.1.1. DIABETES DRUGS Market Revenue Share, By Diabetes Types, 2023 & 2032 59

14.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Diabetes Types 60

14.1.3. Incremental Revenue Growth Opportunity, by Diabetes Types, 2024 – 2032 60

14.1.4. DIABETES DRUGS Market Revenue, By Diabetes Types, 2018, 2023, 2027 & 2032 61

14.2. Type 1 62

14.3. Type 2 63

14.4. Diabetes Types 3 64

14.5. Diabetes Types 4 65

14.6. Diabetes Types 5 66

CHAPTER NO. 15 : DIABETES DRUGS MARKET – BY ROUTE OF ADMINISTRATION SEGMENT ANALYSIS 67

15.1. DIABETES DRUGS Market Overview, by Route Of Administration Segment 67

15.1.1. DIABETES DRUGS Market Revenue Share, By Route Of Administration , 2023 & 2032 68

15.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Route Of Administration 69

15.1.3. Incremental Revenue Growth Opportunity, by Route Of Administration , 2024 – 2032 69

15.1.4. DIABETES DRUGS Market Revenue, By Route Of Administration , 2018, 2023, 2027 & 2032 70

15.2. Oral 71

15.3. Subcutaneous 72

15.4. Intravenous 73

15.5. Route Of Administration 4 74

15.6. Route Of Administration 5 75

CHAPTER NO. 16 : DIABETES DRUGS MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 76

16.1. DIABETES DRUGS Market Overview, by Technology Segment 76

16.1.1. DIABETES DRUGS Market Revenue Share, By Technology, 2023 & 2032 77

16.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Technology 78

16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 78

16.1.4. DIABETES DRUGS Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

16.2. Technology 1 80

16.3. Technology 2 81

16.4. Technology 3 82

CHAPTER NO. 17 : – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 83

17.1. DIABETES DRUGS Market Overview, by Distribution Channel Segment 83

17.1.1. DIABETES DRUGS Market Revenue Share, By Distribution Channel, 2023 & 2032 84

17.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Distribution Channel 85

17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 85

17.1.4. DIABETES DRUGS Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

17.2. Online Pharmacies 87

17.3. Hospital Pharmacies 88

17.4. Retail Pharmacies 89

17.5. Distribution Channel 4 90

17.6. Distribution Channel 5 91

CHAPTER NO. 18 : DIABETES DRUGS MARKET – CHINA ANALYSIS 92

18.1. Drug Class 92

18.1.1. China DIABETES DRUGS Market Revenue, By Drug Class, 2018 – 2023 (USD Million) 92

18.2. China DIABETES DRUGS Market Revenue, By Drug Class, 2024 – 2032 (USD Million) 92

18.3. Diabetes Types 93

18.3.1. China DIABETES DRUGS Market Revenue, By Diabetes Types, 2018 – 2023 (USD Million) 93

18.3.2. China DIABETES DRUGS Market Revenue, By Diabetes Types, 2024 – 2032 (USD Million) 93

18.4. Route Of Administration 94

18.4.1. China DIABETES DRUGS Market Revenue, By Route Of Administration , 2018 – 2023 (USD Million) 94

18.4.2. China DIABETES DRUGS Market Revenue, By Route Of Administration , 2024 – 2032 (USD Million) 94

18.5. Technology 95

18.5.1. China DIABETES DRUGS Market Revenue, By Technology, 2018 – 2023 (USD Million) 95

18.5.2. China DIABETES DRUGS Market Revenue, By Technology, 2024 – 2032 (USD Million) 95

18.6. Distribution Channel 96

18.6.1. China DIABETES DRUGS Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 96

18.6.2. China DIABETES DRUGS Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 96

CHAPTER NO. 19 : COMPANY PROFILES 97

19.1. Novo Nordisk A/S 97

19.1.1. Company Overview 97

19.1.2. Product Portfolio 97

19.1.3. Swot Analysis 97

19.1.4. Business Strategy 98

19.1.5. Financial Overview 98

19.1.6. Sanofi 99

19.1.7. Merck & Co., Inc 99

19.1.8. Eli Lilly and Company 99

19.1.9. AstraZeneca 99

19.1.10. Takeda Pharmaceutical Company Limited 99

19.1.11. Boehringer Ingelheim International GmbH 99

19.1.12. Novartis AG 99

19.1.13. Johnson & Johnson Services, Inc. 99

19.1.14. Bayer AG 99

19.1.15. Chongqing Fujin Biology Medical Company 99

19.1.16. Hisun Pharma 99

19.1.17. Company 13 99

19.1.18. Company 14 99

CHAPTER NO. 20 : RESEARCH METHODOLOGY 100

20.1. Research Methodology 100

20.1.1. Phase I – Secondary Research 101

20.1.2. Phase II – Data Modeling 101

Company Share Analysis Model 102

Revenue Based Modeling 102

20.1.3. Phase III – Primary Research 103

20.1.4. Research Limitations 104

Assumptions 104

List of Figures

FIG NO. 1. China DIABETES DRUGS Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for China DIABETES DRUGS Market 29

FIG NO. 3. Value Chain Analysis for China DIABETES DRUGS Market 30

FIG NO. 4. China DIABETES DRUGS Market Import Volume/Revenue, By China, 2018 – 2023 32

FIG NO. 5. China DIABETES DRUGS Market Export Volume/Revenue, By China, 2018 – 2023 33

FIG NO. 6. China DIABETES DRUGS Market Demand Volume/Revenue, By China, 2018 – 2023 34

FIG NO. 7. China DIABETES DRUGS Market Supply Volume/Revenue, By China, 2018 – 2023 35

FIG NO. 8. China DIABETES DRUGS Market Production Volume/Revenue, By China, 2018 – 2023 36

FIG NO. 9. China DIABETES DRUGS Market Price, By Drug Class, 2018 – 2023 37

FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38

FIG NO. 11. Manufacturing Cost Analysis 39

FIG NO. 12. Manufacturing Process 39

FIG NO. 13. Company Share Analysis, 2023 40

FIG NO. 14. Company Share Analysis, 2023 41

FIG NO. 15. Company Share Analysis, 2023 41

FIG NO. 16. Company Share Analysis, 2023 42

FIG NO. 17. DIABETES DRUGS Market – Company Volume Market Share, 2023 43

FIG NO. 18. DIABETES DRUGS Market – Company Revenue Market Share, 2023 44

FIG NO. 19. DIABETES DRUGS Market Revenue Share, By Drug Class, 2023 & 2032 50

FIG NO. 20. Market Attractiveness Analysis, By Drug Class 51

FIG NO. 21. Incremental Revenue Growth Opportunity by Drug Class, 2024 – 2032 51

FIG NO. 22. DIABETES DRUGS Market Revenue, By Drug Class, 2018, 2023, 2027 & 2032 52

FIG NO. 23. China DIABETES DRUGS Market for Insulin, Revenue (USD Million) 2018 – 2032 53

FIG NO. 24. China DIABETES DRUGS Market for Dpp-4 Inhibitors, Revenue (USD Million) 2018 – 2032 54

FIG NO. 25. China DIABETES DRUGS Market for GLP-1 Receptor Agonists, Revenue (USD Million) 2018 – 2032 55

FIG NO. 26. China DIABETES DRUGS Market for SGLT2 Inhibitors, Revenue (USD Million) 2018 – 2032 56

FIG NO. 27. China DIABETES DRUGS Market for Others, Revenue (USD Million) 2018 – 2032 57

FIG NO. 28. DIABETES DRUGS Market Revenue Share, By Diabetes Types, 2023 & 2032 59

FIG NO. 29. Market Attractiveness Analysis, By Diabetes Types 60

FIG NO. 30. Incremental Revenue Growth Opportunity by Diabetes Types, 2024 – 2032 60

FIG NO. 31. DIABETES DRUGS Market Revenue, By Diabetes Types, 2018, 2023, 2027 & 2032 61

FIG NO. 32. China DIABETES DRUGS Market for Type 1, Revenue (USD Million) 2018 – 2032 62

FIG NO. 33. China DIABETES DRUGS Market for Type 2, Revenue (USD Million) 2018 – 2032 63

FIG NO. 34. China DIABETES DRUGS Market for Diabetes Types 3, Revenue (USD Million) 2018 – 2032 64

FIG NO. 35. China DIABETES DRUGS Market for Diabetes Types 4, Revenue (USD Million) 2018 – 2032 65

FIG NO. 36. China DIABETES DRUGS Market for Diabetes Types 5, Revenue (USD Million) 2018 – 2032 66

FIG NO. 37. DIABETES DRUGS Market Revenue Share, By Route Of Administration , 2023 & 2032 68

FIG NO. 38. Market Attractiveness Analysis, By Route Of Administration 69

FIG NO. 39. Incremental Revenue Growth Opportunity by Route Of Administration , 2024 – 2032 69

FIG NO. 40. DIABETES DRUGS Market Revenue, By Route Of Administration , 2018, 2023, 2027 & 2032 70

FIG NO. 41. China DIABETES DRUGS Market for Oral, Revenue (USD Million) 2018 – 2032 71

FIG NO. 42. China DIABETES DRUGS Market for Subcutaneous, Revenue (USD Million) 2018 – 2032 72

FIG NO. 43. China DIABETES DRUGS Market for Intravenous, Revenue (USD Million) 2018 – 2032 73

FIG NO. 44. China DIABETES DRUGS Market for Route Of Administration 4, Revenue (USD Million) 2018 – 2032 74

FIG NO. 45. China DIABETES DRUGS Market for Route Of Administration 5, Revenue (USD Million) 2018 – 2032 75

FIG NO. 46. DIABETES DRUGS Market Revenue Share, By Technology, 2023 & 2032 77

FIG NO. 47. Market Attractiveness Analysis, By Technology 78

FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78

FIG NO. 49. DIABETES DRUGS Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

FIG NO. 50. China DIABETES DRUGS Market for Technology 1, Revenue (USD Million) 2018 – 2032 80

FIG NO. 51. China DIABETES DRUGS Market for Technology 2, Revenue (USD Million) 2018 – 2032 81

FIG NO. 52. China DIABETES DRUGS Market for Technology 3, Revenue (USD Million) 2018 – 2032 82

FIG NO. 53. DIABETES DRUGS Market Revenue Share, By Distribution Channel, 2023 & 2032 84

FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85

FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85

FIG NO. 56. DIABETES DRUGS Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

FIG NO. 57. China DIABETES DRUGS Market for Online Pharmacies, Revenue (USD Million) 2018 – 2032 87

FIG NO. 58. China DIABETES DRUGS Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 88

FIG NO. 59. China DIABETES DRUGS Market for Retail Pharmacies, Revenue (USD Million) 2018 – 2032 89

FIG NO. 60. China DIABETES DRUGS Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90

FIG NO. 61. China DIABETES DRUGS Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91

FIG NO. 62. Research Methodology – Detailed View 100

FIG NO. 63. Research Methodology 101

List of Tables

TABLE NO. 1. : China DIABETES DRUGS Market: Snapshot 18

TABLE NO. 2. : Drivers for the DIABETES DRUGS Market: Impact Analysis 22

TABLE NO. 3. : Restraints for the DIABETES DRUGS Market: Impact Analysis 24

TABLE NO. 4. : China DIABETES DRUGS Market Revenue, By Drug Class, 2018 – 2023 34

TABLE NO. 5. : Key Raw Materials & Suppliers 35

TABLE NO. 6. : China DIABETES DRUGS Market Revenue, By Drug Class, 2018 – 2023 (USD Million) 89

TABLE NO. 7. : China DIABETES DRUGS Market Revenue, By Drug Class, 2024 – 2032 (USD Million) 89

TABLE NO. 8. : China DIABETES DRUGS Market Revenue, By Diabetes Types, 2018 – 2023 (USD Million) 90

TABLE NO. 9. : China DIABETES DRUGS Market Revenue, By Diabetes Types, 2024 – 2032 (USD Million) 90

TABLE NO. 10. : China DIABETES DRUGS Market Revenue, By Route Of Administration , 2018 – 2023 (USD Million) 91

TABLE NO. 11. : China DIABETES DRUGS Market Revenue, By Route Of Administration , 2024 – 2032 (USD Million) 91

TABLE NO. 12. : China DIABETES DRUGS Market Revenue, By Technology, 2018 – 2023 (USD Million) 92

TABLE NO. 13. : China DIABETES DRUGS Market Revenue, By Technology, 2024 – 2032 (USD Million) 92

TABLE NO. 14. : China DIABETES DRUGS Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93

TABLE NO. 15. : China DIABETES DRUGS Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93

Frequently Asked Questions

What is the current size of the China Diabetes Drugs Market?

The China Diabetes Drugs market was valued at USD 9,595.27 million in 2023 and is projected to reach USD 15,556.98 million by 2032, growing at a CAGR of 5.11% during the forecast period.

What factors are driving the growth of the China Diabetes Drugs Market?

Market growth is fueled by the rising prevalence of diabetes due to an aging population, urbanization, and changing lifestyles. Additionally, advancements in drug development, government healthcare initiatives, digital health integration, and increasing collaborations between global and domestic pharmaceutical companies contribute to expansion.

What are some challenges faced by the China Diabetes Drugs Market?

High treatment costs, limited access to advanced therapies in rural areas, and complex regulatory processes are key challenges. Additionally, market competition from biosimilars and pricing pressures impact affordability and patient accessibility.

Who are the major players in the China Diabetes Drugs Market?

Key players include Novo Nordisk, Sanofi, Merck & Co., Eli Lilly, AstraZeneca, Boehringer Ingelheim, Takeda Pharmaceutical, Novartis, Johnson & Johnson, Bayer, Chongqing Fujin Biology Medical Company, and Hisun Pharma. These companies focus on R&D, strategic collaborations, and digital health advancements to strengthen their market position.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –